Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine hydrobromide or glycopyrronium bromide versus placebo for clozapine-induced hypersalivation
ISRCTN36536677Phase 3Active, not recruiting
- Sponsor
- University of Liverpool
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of scopolamine, glycopyrronium and Placebo-COD Research Private Ltd in clozapine-induced hypersalivation (CIS) (3 arms), sponsored by University of Liverpool. Started Aug 2024; status: active, not recruiting.
02
Drugs
scopolamineglycopyrroniumPlacebo-COD Research Private Ltd
03
Conditions
clozapine-induced hypersalivation (CIS)
Beyond the preview
Go deeper on ISRCTN36536677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36536677.